May 9 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.22.COLLABORATION REVENUE TOTALED $20.41 MILLION FOR Q1 ENDED MARCH 31, 2019, COMPARED TO $9.29 MILLION FOR SAME PERIOD IN 2018.QTRLY LOSS PER SHARE $0.22.
Full Article

April 29 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE LTD SAYS CEO JOHN V. OYLER'S TOTAL COMPENSATION FOR FY 2018 WAS $27.9 MILLION VERSUS $10.3 MILLION IN FY 2017- SEC FILING.BEIGENE LTD SAYS GENERAL MANAGER OF CHINA AND PRESIDENT XIAOBIN WU'S TOTAL COMPENSATION FOR FY 2018 WAS $21.5 MILLION.BEIGENE LTD - RATIO OF 2018 ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL EMPLOYEES IS 135:1.
Full Article

April 9 (Reuters) - Beigene Ltd <6160.HK>::BIOATLA AND BEIGENE FORM WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE NOVEL CONDITIONALLY ACTIVE BIOLOGIC CTLA-4 THERAPY.BIOATLA LLC - WILL RECEIVE AN UPFRONT PAYMENT OF $20 MILLION AND A MILESTONE PAYMENT UPON REACHING DEFINED EARLY CLINICAL OBJECTIVES.BIOATLA - BEIGENE WILL HOLD A CO-EXCLUSIVE LICENSE WITH BIOATLA TO DEVELOP AND MANUFACTURE PRODUCT CANDIDATE GLOBALLY.BIOATLA - IS ALSO ELIGIBLE TO RECEIVE UP TO $249 MILLION IN MILESTONE PAYMENTS.
Full Article

Nov 27 (Reuters) - Beigene Ltd <6160.HK>::ZYMEWORKS AND BEIGENE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT FOR ZYMEWORKS’ HER2-TARGETED THERAPEUTIC CANDIDATES, ZW25 AND ZW49, IN ASIA-PACIFIC AND RESEARCH AND LICENSE AGREEMENT FOR ZYMEWORKS’ AZYMETRIC™ AND EFECT™ PLATFORMS GLOBALLY.ZYMEWORKS INC - ZYMEWORKS WILL RECEIVE TOTAL UPFRONT PAYMENTS OF US$40 MILLION UNDER ZW25 AND ZW49 AGREEMENTS AND US$20 MILLION UNDER PLATFORM AGREEMENT.ZYMEWORKS INC - BEIGENE ACQUIRES EXCLUSIVE DEVELOPMENT AND COMMERCIAL RIGHTS TO ZYMEWORKS' BISPECIFIC CANDIDATES, ZW25 AND ZW49, IN ASIA.ZYMEWORKS INC - BEIGENE ALSO ACQUIRES LICENSES FOR ZYMEWORKS' AZYMETRIC AND EFECT PLATFORMS.ZYMEWORKS INC - BEIGENE ACQUIRES EXCLUSIVE RIGHTS TO ZW25 AND ZW49, IN ASIA (EXCLUDING JAPAN), AUSTRALIA, AND NEW ZEALAND.ZYMEWORKS INC - ZYMEWORKS ELIGIBLE TO RECEIVE DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS PLUS POTENTIAL ROYALTIES ON PRODUCT SALES..ZYMEWORKS - IS ELIGIBLE TO RECEIVE UP TO US$390 MILLION IN DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS FOR BOTH PRODUCT CANDIDATES.ZYMEWORKS - UNDER TERMS OF AGREEMENT FOR AZYMETRIC AND EFECT PLATFORMS, CO ELIGIBLE TO RECEIVE UP TO AN AGGREGATE OF US$702 MILLION IN MILESTONE PAYMENTS.ZYMEWORKS - ELIGIBLE TO GET UPTO $702 MILLION IN DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS FOR UP TO 3 BISPECIFIC PRODUCT CANDIDATES DEVELOPED.
Full Article

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: